| Date | Title | |
| 06/17/13 | Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease| Treatment indicated for patients with transfusion-dependent
anaemia due to myelodysplastic syndromes (MDS) with an isolated
chromosomal abnormality called deletion 5q
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 17, 2013--
Celgene International Sàrl (NASDAQ: CELG) was today notified that the
European Commission (EC) has amended the marketing authorisation for
REVLIMID®. This decision means that REVLIMID is now approved
to treat patients with tra... |
|  |
| 06/14/13 | Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet’s Disease| Statistically Significant Results in Primary and All Secondary
Endpoints Achieved in Rare Orphan Disease
No Approved Therapies in US or Europe for Rare Chronic Inflammatory
Disorder
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 14, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today presented results from a randomized, placebo-controlled
phase II trial in patients with Behçet’s disease (BD) ... |
| |
| 06/13/13 | Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR| Signs and symptoms in patients with psoriatic arthritis significantly
Improved with apremilast treatment in PALACE 3
Patients treated with apremilast demonstrated improvement across key
secondary endpoints in PALACE 3
Safety and tolerability profile in PALACE 3 was comparable to
previously-reported PALACE studies
ABSTRACT #SAT0299; OP0104; SAT0280
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 13, 2013--
Celgene Inte... |
| |
| 06/12/13 | Celgene Announces Additional $3.0 Billion Share Repurchase Program| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 12, 2013--
Celgene Corporation (NASDAQ: CELG) announced today that its Board of
Directors authorized the repurchase of up to an additional $3.0 billion
of the Company’s common stock. Purchases may be made in the open market
or in privately negotiated transactions from time to time, as determined
by management and in accordance with applicable requirements of the
Securities and Exchange Commission.
Year-t... |
| |
| 06/12/13 | Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1)| 52-week data revealed improving efficacy over time, reporting ACR 20
scores to 63% and 55% for the two apremilast dose groups; similar
improvements reported in ACR 50 and ACR 70 scores
PALACE 1 apremilast data selected for inclusion at EULAR press
conference
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 12, 2013--
ABSTRACT #LB0001
Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG), t... |
| |
| 06/06/13 | Celgene Corporation to Webcast at Upcoming Investor Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 6, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at an upcoming
investor conference this month. The conference will be webcast live and
the webcast will be available in the Investor Relations section of the
Company’s website at www.celgene.com.
Celgene management will provide an overview of the Company.
Wednesday, June 19, 2013 Celgene will present at the Wells Fargo 2013
Healthcare Conferen... |
| |
| 06/05/13 | U.S. Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 5, 2013--
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and
Drug Administration (FDA) has approved the company’s supplemental new
drug application (sNDA) for REVLIMID® (lenalidomide) for the
treatment of patients with mantle cell lymphoma (MCL) whose disease has
relapsed or progressed after two prior therapies, one of which included
bortezomib.
“There remains a tremendous unmet need fo... |
| |
| 06/03/13 | Updated Studies Evaluating POMALYST® (pomalidomide) In Previously Treated Multiple Myeloma Patients Presented at ASCO| BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 3, 2013--
Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG), today announced updated data from MM-003,
the Company’s phase III international study evaluating POMALYST®
(pomalidomide) plus low-dose dexamethasone versus high-dose
dexamethasone in relapsed or refractory multiple myeloma patients who
had received at least two prior treatment regimens, failed both
lena... |
| |
| 06/03/13 | Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO| MEL200 demonstrated a longer median PFS and OS compared to MPR in the
study
REVLIMID maintenance therapy demonstrated a statistically significant
reduction in the risk of disease progression and significant improvement
in overall survival regardless of previous treatment
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 3, 2013--
Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG), today announced data ... |
| |
| 06/03/13 | Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at ASCO 2013| Data Suggest Treatment with ABRAXANE plus Gemcitabine Reduces Levels
of CA19-9 and Increases the Frequency of PET Responses; Both Tools Found
to be Potential Prognostic Factors of Overall Survival
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 3, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), announced several analyses of a phase III clinical trial of
ABRAXANE® (paclitaxel protein-bound particles for injectable
... |
| |
| 05/31/13 | Celgene Announces Launch of “Innovation Impact” Awards to Recognize Excellence in Creative Patient, Caregiver or Healthcare Provider Programs| Deadline for Applications is July 31st,
2013; Submissions Accepted Online Only at www.innovationimpact.com
SUMMIT, N.J.--(BUSINESS WIRE)--May. 31, 2013--
Celgene Corporation (NASDAQ: CELG), announced today the initiation of
the “Innovation Impact” Awards to recognize effective, innovative and
successful initiatives in one of two therapeutic areas: hematology or
oncology. The program aims to recognize the achievements of US-based
not-for-profit... |
| |
| 05/31/13 | Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma| BOUDRY, Switzerland--(BUSINESS WIRE)--May. 31, 2013--
Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG), today announced that the European Medicines
Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP)
has adopted a positive opinion for Pomalidomide Celgene in combination
with dexamethasone for the treatment of relapsed and refractory multiple
myeloma (rrMM) in patients who have received at least... |
| |
| 05/23/13 | Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer| European Medicines Agency Accepts Regulatory Submission of Type II
Variation for ABRAXANE for the Treatment of Advanced Pancreatic Cancer
BOUDRY, Switzerland--(BUSINESS WIRE)--May. 23, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation
(Celgene) (NASDAQ: CELG) today announced that the U.S. Food and Drug
Administration (FDA) has assigned a Priority Review designation to the
supplemental New Drug Application (sNDA) for the use of AB... |
| |
| 05/06/13 | Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients with Psoriatic Arthritis| PALACE 4 was the first apremilast trial in DMARD-naïve patients and
included more than 500 patients
No new safety and tolerability signals identified, with fewer AEs and
SAEs reported than in (PALACE 1, 2&3)
Apremilast NDA/NDS for psoriatic arthritis submitted to health
authorities in the US and Canada in Q1’2013 and Q2’2013 respectively
Apremilast NDA in US for psoriasis and combined psoriatic
arthritis/psoriasis MAA s... |
| |
| 04/29/13 | Celgene Corporation to Webcast at Upcoming Investor Conferences and Analyst Day| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 29, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming
investor conferences in May. The conferences will be webcast live and
the webcasts will be available in the Investor Relations section of the
Company’s website at www.celgene.com.
Celgene management will provide an overview of the Company.
Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock
Conference at 1... |
| |
| 04/26/13 | Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients with Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes| BOUDRY, Switzerland--(BUSINESS WIRE)--Apr. 26, 2013--
Celgene International Sàrl (NASDAQ: CELG) today announced the European
Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use
(CHMP) has adopted a positive opinion for REVLIMID®
for the treatment of patients with transfusion-dependent anemia due to
low or intermediate-1-risk myelodysplastic syndromes (MDS) associated
with an isolated deletion 5q cytogenetic abnormality when other
... |
| |
| 04/25/13 | Celgene Reports First Quarter 2013 Operating and Financial Results| — Net Product Sales of $1.43 Billion, Increased 15 Percent Y/Y
— Total Revenue of $1.46 Billion, Increased 15 Percent Y/Y
— Adjusted Diluted Earnings Per Share of $1.37, Increased 27 Percent
Y/Y
—2013 Adjusted Diluted EPS Guidance Raised; Net Product Sales
Guidance Affirmed
SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 25, 2013--
Celgene Corporation (NASDAQ: CELG) reported net product sales of $1,429
million for the first ... |
| |
| 04/03/13 | Celgene Corporation to Announce First Quarter 2013 Results on April 25, 2013| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 3, 2013--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, April 25, 2013 at 9
a.m. ET to discuss the company’s first quarter 2013 financial and
operational results. The webcast will be available in the investor
relations section of the Company’s Web site at www.celgene.com.
About Celgene
Celgene Corporation, headquartered in Sum... |
| |
| 03/02/13 | Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of PASI-75 in the First Phase III Study (ESTEEM 1) in Patients with Psoriasis|
Apremilast significantly improved signs and symptoms of psoriasis
across a range of patient types—from systemic treatment-naïve to
biologic-treatment failure patients
Apremilast demonstrated significant improvement in the primary
endpoint and major secondary endpoint in the study
No new safety signals were observed; safety and tolerability
consistent with phase III psoriatic arthritis trials
BOUDRY, Switzerland--(BUSINE... |
| |
| 02/28/13 | Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the American Academy of Dermatology Annual Meeting| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 28, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming
investor conferences. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Tuesday, March 5, 2013 Celgene will present at the Cowen and Company
33rd Annual Health Care Conference at 11:... |
| |
| 02/27/13 | The European Organisation for Rare Diseases (EURORDIS) Awards Celgene Corporation for Excellence in Medical Innovation in Rare Diseases| BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 27, 2013--
EURORDIS (The European Organisation for Rare Diseases) announced today
that Celgene Corporation (NASDAQ:CELG) has been awarded the prestigious
EURORDIS Company Award for excellence in the field of rare diseases. The
award, presented just in advance of Rare Diseases Day, February 28,
recognises Celgene’s established track record in the area of orphan
diseases, with multiple orphan designations and ... |
| |
| 02/20/13 | Celgene Announces $600 Million Accelerated Share Repurchase Program| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 20, 2013--
Celgene Corporation (NASDAQ: CELG) announced today that it has entered
into an accelerated share repurchase (ASR) agreement with an investment
bank to repurchase an aggregate of $600 million of the company’s common
stock. The ASR is part of the existing Board authorized share repurchase
program. Year-to-date, Celgene has repurchased approximately $385
million of its common stock and has approximately $1,... |
| |
| 02/11/13 | Celgene Provides REVLIMID® Regulatory Update|
REVLIMID Granted Approval for Treatment of Patients with Relapsed or
Refractory Multiple Myeloma in China
REVLIMID Granted Priority Review as Treatment for Patients with
Relapsed or Refractory Mantle Cell Lymphoma - U.S. FDA PDUFA Date Set
for June 5, 2013
BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 11, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), today announced that REVLIMID® (lenalido... |
| |
| 02/08/13 | U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 8, 2013--
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and
Drug Administration (FDA) has approved POMALYST® brand
therapy (pomalidomide) for patients with multiple myeloma who have
received at least two prior therapies including lenalidomide and
bortezomib and have demonstrated disease progression on or within 60
days of completion of the last therapy.
POMALYST(R) brand therapy (P... |
| |
| 02/04/13 | Celgene Corporation to Webcast at Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 4, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming
investor conferences. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Monday, February 11, 2013 Celgene will present at the 15th Annual BIO
CEO & Investor Conference at 8:00 a... |
| |
| 01/24/13 | Celgene Reports Strong Fourth Quarter and Full Year 2012 Operating and Financial Results|
Total Revenues of $5.5 Billion, Increased 14 Percent Y/Y
Adjusted Diluted Earnings per Share of $4.91, Increased 30 Percent
Y/Y; GAAP Diluted Earnings per Share of $3.30 Increased 16 Percent Y/Y
New and Updated Data on Over Ten Pivotal Phase III Trials Expected in
2013
Affirms 2013 Financial Outlook
SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 24, 2013--
Celgene Corporation (NASDAQ: CELG) reported net product sales of $1... |
| |
| 01/22/13 | ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer|
Abraxane plus gemcitabine was superior to gemcitabine alone with
statistically significant and clinically meaningful results across
primary and key secondary endpoints and patient subgroups
Oral Presentation Scheduled for Friday, January 25th
at ASCO’s Gastrointestinal Cancers Symposium Annual Meeting
BOUDRY, Switzerland--(BUSINESS WIRE)--Jan. 22, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
C... |
| |
| 01/07/13 | Celgene Corporation Announces Financial Outlook and Preliminary 2012 Results|
2012 Adjusted Diluted EPS Expected to be at the Higher End of
Previous Guidance Range at Approximately $4.90 (GAAP Range $3.37 to
$3.39)
REVLIMID® Achieved Q4 2012 Net Sales of Just
Over $1.0 Billion
2013 Guidance: Total Net Product Sales of $6.0 Billion; REVLIMID $4.1
Billion to $4.2 Billion; Adjusted Diluted EPS $5.50 to $5.60 (GAAP Range
$4.67 to $4.79)
Long-Term 2015 Targets of $8.0- 9.0 Billion in Total ... |
| |
| 01/07/13 | Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint in Pivotal Phase III Psoriasis Trials|
Clinical Data from two pivotal phase III (ESTEEM 1&2) randomized,
placebo-controlled studies including approximately 1,250 patients
demonstrated statistically significant and clinically meaningful
improvements for the primary and major secondary endpoint
NDA submission based on ESTEEM program in psoriasis planned for
H2’2013; MAA submission for psoriasis and psoriatic arthritis planned
for H2’2013
No new safety signals ... |
| |
